Ecolab (ECL)
(Delayed Data from NYSE)
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
Factors Setting the Tone for Ecolab's (ECL) Q1 Earnings
by Zacks Equity Research
Ecolab's (ECL) first-quarter results are likely to reflect continued segmental strength.
Reliance's (RS) Earnings & Revenues Miss Estimates in Q1
by Zacks Equity Research
Reliance's (RS) first-quarter earnings and sales lag their respective estimates on lower shipments and prices.
Agnico Eagle's (AEM) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Agnico Eagle's (AEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.
DexCom (DXCM) Q1 Earnings Beat, Strong CGM Demand Continues
by Zacks Equity Research
DexCom's (DXCM) first-quarter 2024 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Newmont's (NEM) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Newmont's (NEM) first-quarter earnings and revenues exceed expectations, driven by increased production and higher realized gold prices.
Revvity's (RVTY) New Launch to Boost Tuberculosis Testing
by Zacks Equity Research
Revvity's (RVTY) latest offering is likely to provide a new and improved workflow to lower hands-on time and enable increased lab productivity.
CONMED (CNMD) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) adjusted first-quarter earnings and revenues beat estimates on the back of strong U.S. and International markets as well as supply-chain improvement.
Veeva's (VEEV) AI Partner Program to Develop GenAI Solutions
by Zacks Equity Research
Veeva (VEEV) announces the Veeva AI Partner Program, which is expected to provide partners assistance to combine Generative AI solutions with Veeva Vault applications.
West Pharmaceutical (WST) Q1 Earnings Beat, HVP Sales Weak
by Zacks Equity Research
West Pharmaceutical's (WST) first-quarter results reflect a strong demand for non-COVID-19 products, especially HVP devices.
Unveiling Ecolab (ECL) Q1 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Ecolab (ECL), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Methanex's (MEOH) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Adjusted EBITDA of Methanex (MEOH) is hurt by lower year-over-year average realized prices in Q1.
Cleveland-Cliffs (CLF) Earnings & Revenues Lag Estimates in Q1
by Zacks Equity Research
Cleveland-Cliffs (CLF) lags Q1 earnings and revenue estimates due to lower volumes.
Penumbra's (PEN) New Launch to Enhance Blood Clot Removal
by Zacks Equity Research
Penumbra's (PEN) latest offering is likely to enable physicians to restore blood flow more quickly and further minimize blood loss.
Ingevity (NGVT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Ingevity (NGVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the iShares U.S. Basic Materials ETF (IYM)?
by Zacks Equity Research
Sector ETF report for IYM
Air Products (APD) to Build Hydrogen Refueling Station Network
by Zacks Equity Research
Air Products (APD) has currently installed a temporary hydrogen mobile fueler on-site to supply to customers.
Reasons Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) sustained strength in HSAs raises optimism about the stock.
GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
GE HealthCare's (GEHC) latest partnership is likely to benefit global healthcare systems by enhancing Elekta's RT offerings with its MIM Software medical imaging management solutions.
Sherwin-Williams' (SHW) Q1 Earnings & Sales Lag Estimates
by Zacks Equity Research
Consolidated net sales of Sherwin-Williams (SHW) decline mainly due to a decrease in volumes in the Consumer Brands Group and the Performance Coatings Group in North America in Q1.
Ecolab (ECL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Ecolab (ECL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights Atmos Energy, Ecolab and The Sherwin-Williams
by Zacks Equity Research
Atmos Energy, Ecolab and The Sherwin-Williams are part of the Zacks top Analyst Blog.
3 Dividend Aristocrats to Take the Edge off Market Volatility
by Tirthankar Chakraborty
With markets remaining topsy-turvy, it's prudent for astute investors to pick dividend aristocrats like Atmos Energy (ATO), Ecolab (ECL) and SherwinWilliams (SHW) for steady income.
Play Disaster Recovery Stocks on Earth Day
by Sanghamitra Saha
Global warming has been wreaking havoc on earth and causing natural disasters. Hence, these disaster recovery stocks could be prudent investing options on Earth Day.
Cabot (CBT) Chosen for $5M DOE Grant to Aid Hydrogen Economy
by Zacks Equity Research
Cabot (CBT) and its partners will utilize this money to help the implementation of fuel cells, which generate electricity by emitting only water.
Reasons Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.